Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Chemotherapy-induced Neutropenia 2

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × NPI 2358 × Clear all
NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡